Psychemedics Corporation (PMD)
NASDAQ: PMD · IEX Real-Time Price · USD
2.570
-0.050 (-1.91%)
At close: Apr 26, 2024, 3:57 PM
2.550
-0.020 (-0.78%)
After-hours: Apr 26, 2024, 4:00 PM EDT

Company Description

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally.

It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol.

The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time.

It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use.

The company was incorporated in 1986 and is headquartered in Dallas, Texas.

Psychemedics Corporation
Psychemedics logo
Country United States
Founded 1986
Industry Diagnostics & Research
Sector Healthcare
Employees 116
CEO Brian Hullinger

Contact Details

Address:
125 Nagog Park
Acton, Massachusetts 01720
United States
Phone 978-206-8220
Website psychemedics.com

Stock Details

Ticker Symbol PMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000806517
CUSIP Number 744375205
ISIN Number US7443752057
Employer ID 58-1701987
SIC Code 8071

Key Executives

Name Position
Brian Hullinger President, Chief Executive Officer and Director
Daniella Mehalik Vice President of Finance
Shannon Shoemaker Chief Revenue Officer
Dr. Werner A. Baumgartner Ph.D. Founder
Annette Baumgartner Founder
Michael Weisenhoff Principal Financial and Accounting Manager
Patrick J. Kinney Jr. Secretary

Latest SEC Filings

Date Type Title
Mar 28, 2024 10-K Annual Report
Mar 28, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 26, 2024 8-K Current Report
Dec 14, 2023 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 27, 2023 8-K Current Report
Nov 13, 2023 10-Q Quarterly Report
Nov 9, 2023 8-K Current Report
Nov 8, 2023 8-K Current Report